Cipla 경영진
경영진 기준 점검 0/4
현재 CEO에 대한 정보가 충분하지 않습니다.
핵심 정보
Achin Gupta
최고경영자
n/a
총 보수
| CEO 급여 비율 | n/a |
| CEO 재임 기간 | less than a year |
| CEO 지분 보유율 | n/a |
| 경영진 평균 재임 기간 | 1.2yrs |
| 이사회 평균 재임 기간 | 2yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jun 22
CIPLA: Fair Outlook As Respiratory Diagnostics And US Generics Pipeline Evolve
Analysts have marginally reduced their fair value estimate for Cipla, trimming the price target from about ₹1,460 to roughly ₹1,457 as they fine-tune assumptions on long term profit margins and forward P/E multiples, while keeping core growth expectations broadly unchanged. What’s in the News for Cipla Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases such as COPD and asthma, built on US FDA cleared technology and approved by India’s CDSCO.내러티브 업데이트 • Jun 05
CIPLA: Fair Outlook As New CEO And Respiratory Portfolio Changes Take Shape
Analysts have raised their price target on Cipla by about ₹30 to ₹1,459.57, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple, alongside a marginally higher discount rate. What's in the News Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases like COPD and asthma.분석 기사 • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...내러티브 업데이트 • Apr 27
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.내러티브 업데이트 • Apr 12
CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).내러티브 업데이트 • Mar 27
CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).내러티브 업데이트 • Mar 13
CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).내러티브 업데이트 • Feb 27
CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).내러티브 업데이트 • Feb 13
CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).내러티브 업데이트 • Jan 30
CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).분석 기사 • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...분석 기사 • Jan 17
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...내러티브 업데이트 • Jan 16
CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).분석 기사 • Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...분석 기사 • Sep 24
Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...분석 기사 • Sep 06
Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...내러티브 업데이트 • Sep 04
Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.분석 기사 • Jul 13
Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
새로운 내러티브 • Nov 10
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.CEO
Achin Gupta (50 yo)
less than a year
재임 기간
Mr. Achin Gupta serves as Managing Director, Global Chief Executive Officer and Director of Cipla Limited since April 01, 2026. He served as Chief Executive Officer of One India Business at Cipla Limited s...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| MD, Global CEO & Director | less than a year | 데이터 없음 | 데이터 없음 | |
| President & Global Chief Integrated Product Development | less than a year | 데이터 없음 | 데이터 없음 | |
| Global Chief Financial Officer | 3.9yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Head of Corporate Finance | no data | 데이터 없음 | 데이터 없음 | |
| Global Chief Information Officer | 2yrs | 데이터 없음 | 데이터 없음 | |
| Head of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Compliance Officer & Company Secretary | 9.4yrs | ₹15.30m | 데이터 없음 | |
| Global Chief General Counsel | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief of Corporate Communication | no data | 데이터 없음 | 데이터 없음 | |
| Global Chief People Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Global Chief Medical Officer | 2yrs | 데이터 없음 | 데이터 없음 | |
| Head of Cipla Foundation | no data | 데이터 없음 | 데이터 없음 |
1.2yrs
평균 재임 기간
56yo
평균 나이
경험이 풍부한 관리: CIPLA의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.2 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| MD, Global CEO & Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Non-Executive Chairman | 54yrs | ₹25.80m | 18.63% ₹ 219.2b | |
| Non Executive Director | 12yrs | ₹26.50m | 데이터 없음 | |
| Non-Executive Director | 1.7yrs | ₹26.30m | 1.35% ₹ 15.9b | |
| Independent Director | 1.8yrs | ₹9.80m | 데이터 없음 | |
| Independent Director | 1.7yrs | ₹11.00m | 데이터 없음 | |
| Independent Director | 4yrs | ₹9.30m | 데이터 없음 | |
| Independent Vice-Chairman & Lead Independent Director | 5yrs | ₹11.00m | 데이터 없음 | |
| Independent Director | 2.3yrs | ₹9.20m | 데이터 없음 | |
| Non-Executive Non Independent Director | 1.8yrs | ₹25.90m | 데이터 없음 |
2.0yrs
평균 재임 기간
65yo
평균 나이
경험이 풍부한 이사회: CIPLA의 이사회는 경험이 부족한 것으로 간주됩니다(평균 재임 2 년) — 신규 이사회일 가능성이 있습니다.
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/03 12:27 |
| 종가 | 2026/07/03 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Cipla Limited는 54명의 분석가가 다루고 있습니다. 이 중 36명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |